[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Center of Martinique\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":433},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,45,75,104,134,158,180,206,234,266,296,321,348,381,409],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100435402","prevalence-of-helicobacter-pylori-infection-and-gastric-cancer-in-the-west-indies-100435402",false,"NCT04949737","Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies","Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies: Helico-MQ Interventional Study","Hélico-MQ","Inclusion Criteria:\n\n1. Patient over 18 years of age, residing for at least 6 months in Martinique, with a primary diagnosis of gastric cancer\n2. Patient having read the information note and having signed the consent to participate in the study\n3. Patient with social security coverage\n\nExclusion Criteria:\n\n1. Refusal to participate\n2. Patient who could not answer the questionnaires\n3. Patient not affiliated to a social security system\n4. Patient not fluent in French\n5. Patient under legal protection (legal protection, guardianship, curators, etc.)","ALL","18 Years",{"count":20,"type":21},112,"ESTIMATED","OBSERVATIONAL","Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.",[25,26,27],"Stomach Neoplasms","Gastric Neoplasms","Helicobacter Pylori",[27,29,30,31],"Gastric cancer","Prevalence","French West-Indies","RECRUITING","2026-03-26",{"date":35,"type":36},"2026-03-31","ACTUAL",{"date":38,"type":36},"2025-10-09",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"University Hospital Center of Martinique","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100608851","analysis-of-the-determinants-of-the-participation-of-patients-and-health-professionals-of-the-university-hospital-center-of-martinique-in-clinical-research-protocols-in-medical-oncology-studyorec-100608851","NCT07206927","Analysis of the Determinants of the Participation of Patients and Health Professionals of the University Hospital Center of Martinique in Clinical Research Protocols in Medical Oncology (StudyOrec)","Analysis of the Determinants of the Participation of Patients and Health Professionals of the University Hospital Center of Martinique in Clinical Research Protocols in Medical Oncology","Inclusion Criteria for patients group:\n\n* Male or female,\n* Age ≥ 18 years,\n* Patient being treated for cancer at the University Hospital Center of Martinique,\n* Patient who can read and\u002For understand French,\n* Patient who has consented to the use of their medical data for this research.\n\nInclusion Criteria for professionals group:\n\n\\- Any qualified healthcare professional working in the medical oncology departments of the University Hospital Center of Martinique, such as oncologists, radiation therapists, urologists, nurses, etc.\n\nExclusion Criteria for patients group:\n\n* Patient with known cognitive impairments that prevent them from completing the questionnaire,\n* Subjects under legal protection (guardianship\u002Fcuratorship),\n* Subjects at an advanced stage of the disease (asthenia),\n* Written or oral objection from the patient to the use of data for research purposes.\n\nExclusion Criteria for professionals group:\n\n* Students in training regardless of their field,\n* Replacement healthcare professionals for a period of less than 12 months.",true,{"count":54,"type":21},30,"For optimal patient care, it is imperative that healthcare professionals implement appropriate strategies. These strategies must take into account changes in healthcare practices associated with advances in medications and medical equipment. Clinical trials play a crucial role in validating the efficacy and safety of these advances, ensuring high-quality and constantly improving healthcare.\n\nHowever the proportion of patients included in therapeutic trials is often considered too low.\n\nSeveral ideas have been explored to explain the low participation rate in research projects. These are closely linked to research actors and tools, such as, for example:\n\n* the research protocol and its eligibility criteria, which may be overly strict\n* healthcare professionals with the barriers encountered in carrying out research programs (motivation, attitude and perceptions, human, logistical and technical constraints, lack of training)\n* patients who are generally poorly acculturated to clinical research, the lack of information for patients in healthcare services, and patients' lack of trust in the healthcare system.\n* ...\n\nIn Martinique, healthcare professionals face the same challenges in including patients in clinical trials.\n\nPatient inclusion is necessary due to the region's demographic and medical characteristics. To improve patient inclusion in these trials, it is important to define the human and material barriers and levers that influence the participation of patients and healthcare professionals in clinical research protocols in the medical oncology departments of the Martinique University Hospital.\n\nThe investigators believe that increased patient awareness of the benefits of clinical research, equally increased incentives for healthcare professionals, and the establishment of adequate support structures would increase participation in clinical research protocols within the medical oncology departments of the Martinique University Hospital.\n\nBy conducting a mixed qualitative and quantitative study to gather the perspectives of patients and caregivers, the investigators aim to identify the human and material barriers that limit the participation of oncology patients in Martinique.",[57,58,59],"Oncologic Diseases","Cancer","Oncology",[61,62,63,64,65],"clinical research participation","investigation","interrogation","barriers and levers of participation","questionnaire","NOT_YET_RECRUITING","2025-09-26",{"date":69,"type":36},"2025-10-03",{"date":71,"type":21},"2025-10-01",{"date":73,"type":21},"2027-01-01",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":44},"100585993","transcultural-and-psychometric-validation-of-the-lubben-social-network-scale-in-older-adults-living-in-the-french-west-indies-100585993","NCT06909591","Transcultural and Psychometric Validation of the Lubben Social Network Scale in Older Adults Living in the French West Indies","VALLUB","Inclusion Criteria:\n\n* Patient ≥ 65 years old,\n* Hospitalized (Geriatric Day Hospital (HDJ) or Geriatric Medical Care and Rehabilitation Service (SMT)), or seen in geriatric external consultation,\n* MMS ≥ 20,\n* Patient able to understand and answer a self-administered questionnaire in French,\n* Patient having been informed of the research,\n* Patient agreeing to participate in the study.\n\nExclusion Criteria:\n\n* Patient with sensory disorders preventing completion of the questionnaire,\n* Patient unable to consent to participate in the study,\n* Patient under legal protection, guardianship, or curatorship,\n* Patient who has refused to participate in the study.","65 Years",{"count":84,"type":21},150,"Social isolation and loneliness are common among older adults. They are associated with high morbidity and mortality, with an impact comparable to that of other known risk factors such as obesity, a sedentary lifestyle, smoking, etc.\n\nTo date, there is no tool to measure social isolation and loneliness for patients living in the French West Indies. Applying unadapted and unvalidated tools to them without taking into account local ethnocultural realities would be risky.\n\nThe investigators believe it is necessary to adapt the scales used to measure social isolation and loneliness for a population living in the French West Indies.\n\nThrough this study, the investigators propose adapting the Lubben Social Network Scale, a social isolation questionnaire, for this population and conducting its psychometric validation.",[87,88],"Geriatric Assessment","Patients Over 65 Years Old",[90,91,92,93,94,95],"Geriatrics","Lubben Social Network Scale","Transcultural validation","Psychometric validation","Martinique","French West Indies","2025-06-12",{"date":98,"type":36},"2025-06-15",{"date":100,"type":21},"2025-09-01",{"date":102,"type":21},"2027-12-01",{"name":42,"class":43},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":44},"100559149","incidence-characteristics-and-evolution-of-cerebral-vasospasm-with-clinical-impact-in-moderate-to-severe-traumatic-brain-injury-complicated-by-subarachnoid-hemorrhage-at-martinique-university-hospital-100559149","NCT06560372","Incidence, Characteristics and Evolution of Cerebral Vasospasm With Clinical Impact in Moderate to Severe Traumatic Brain Injury Complicated by Subarachnoid Hemorrhage at Martinique University Hospital","VASO-TC","Inclusion Criteria:\n\n* Adult patient aged 18 or over,\n* Hospitalized at the Martinique University Hospital for the treatment or monitoring of a moderate or severe TBI (Glasgow Score less than or equal to 13 at initial treatment) presenting with SAH on the cerebral CT scan,\n* Patient if capable, or representative of the patient in case of incapacity, having been informed of the research, and having given free, informed and written consent,\n* After an emergency inclusion procedure if the patient's representative is initially unreachable and written agreement, informed within the first 48 hours of inclusion by the representative or the patient if his neurological condition allows it,\n* Be affiliated to a social security system.\n\nExclusion Criteria:\n\n* Pregnant woman,\n* Presence of an aneurysmal pathology known or diagnosed at initial treatment,\n* History of chronic kidney failure stage 4 (creatinine clearance measured less than 30ml\u002Fmin),\n* Imminent death of the patient,\n* Patient presenting criteria for non-admission to critical care (death expected within 48 hours, progressive fatal pathology with vital prognosis in less than 30 days, patient in palliative situation),\n* Known allergy to iodized contrast products,\n* Be placed under legal protection, guardianship or curatorship,\n* Patient or representative who refused to allow the patient to participate in the study.\n\nAdditional Exclusion Criteria after patient's inclusion:\n\n* Death of the patient expected within the first 48 hours,\n* Minor,\n* Release from hospitalization against medical advice,\n* Transfer to another establishment before the 13th day of treatment (outside the Martinique University Hospital),\n* Change of opinion of the patient's representative (after neurological recovery) regarding the patient's participation in research,\n* Withdrawal of consent to participate in the study being supported with refusal to use the data collected until withdrawal of participation,",{"count":112,"type":21},154,"INTERVENTIONAL",[115],"NA","Context :\n\nModerate to severe head trauma with altered state of consciousness is an extremely common pathology (between 60 and 120 cases per 100 000 people per year depending on the country and age group), and is responsible for 30% of deaths by trauma. It is complicated in 30-60% of cases by subarachnoid hemorrhage (SAH), which makes it the leading cause of SAH. SAH and its complications are well described when the origin is aneurysmal, notably cerebral vasospasm (CV) because it promotes delayed cerebral ischemia with a major prognostic impact. This is why the screening and prevention of this vasospasm are well established in the literature and in practice, in the nosological context of aneurysmal SAH.\n\nResearch problem :\n\nHowever, when it comes to post-traumatic SAH, CV is a more maligned entity, with a much less detailed description. However, when we know the prognostic interest that it could have for patients, it seems legitimate to seek to define its physiopathological and epidemiological contours. On a prospective cohort of 290 subjects, Oertel et al. (2005) demonstrated, in head trauma patients, an incidence of approximately 40% of compatible signs with the recognized criteria of CV.\n\nTo date, the literature remains sparse on this subject.\n\nProposed study :\n\nIn view of the incomplete scientific literature, the study team wish to carry out a prospective epidemiological study in moderate to severe head trauma patients complicated by SAH and hospitalized at the Martinique University Hospital, with the aim of better characterizing the incidence of the occurrence, and evolution of CV with clinical impact in these patients.\n\nOne of the original aspects of the proposed study is the use of CT scan with perfusion sequence, which has shown its superiority to Transcranial Doppler. The other particularity is its prospective aspect and triggered by an alteration in the clinical state of the patient presenting a traumatic SAH, then directly linking the pathophysiology (cerebral ischemia) and the clinical impact. Thus, the diagnosis of traumatic CV will be made on a cerebral CT scan by the association of the 50% reduction in the caliber of one or more cerebral arteries and a perfusion defect in the perfusion sequence in a context of alteration of neurological clinical examination or deterioration of neurological monitoring parameters. Finally, few studies have monitored the evolution of these patients at 1 and 6 months after the initial event.\n\nHypothesis :\n\nThe research hypothesis is that in the population of moderate to severe head trauma patients hospitalized at the Martinique University Hospital, when a new neurological symptomatology or a deterioration in the state of consciousness occurs, it could be a post-truamatic CV in 15 to 20% of cases.\n\nIndeed, the rare studies find frequencies of radiologically confirmed CV in head trauma patients of around 30-45%, with low numbers of subjects, retrospective studies, or not correlated with the clinic and with the clinical and paraclinical data necessary for the positive diagnosis of this entity. The reported frequency of traumatic CV with clinical impact ranges between 15-20%.\n\nThe study team therefore expect an incidence of 15 to 20% of CV with clinical impact in patients with traumatic SAH in Martinique. CV could be responsible for sudden deterioration of the neurological state in patients suffering from traumatic SAH between the 3rd and 12th day inclusive of treatment (according to retrospective studies already carried out) and responsible for its specific morbidity linked to cerebral ischemia localized in the spasmed area manifested by a worsening of the neurological prognosis on the modified Rankin scale.",[118,119,120,121],"SAH (Subarachnoid Hemorrhage)","Cerebral Vasospasm","Moderate Traumatic Brain Injury","Severe Traumatic Brain Injury",[118,119,123,124,125],"Moderate and severe Traumatic Brain Injury","CT scan","Cerebral perfusion","2025-03-26",{"date":128,"type":36},"2025-03-31",{"date":130,"type":36},"2024-11-06",{"date":132,"type":21},"2028-12-06",{"name":42,"class":43},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":44},"100556431","observational-study-on-mortality-and-outcome-of-patients-hospitalized-for-subarachnoid-hemorrhage-of-aneurysmal-origin-in-martinique-between-2013-and-2021-100556431","NCT06525012","Observational Study on Mortality and Outcome of Patients Hospitalized for Subarachnoid Hemorrhage of Aneurysmal Origin in Martinique Between 2013 and 2021","HSA Rankin","Inclusion Criteria:\n\n* Adult (≥18 years) patients,\n* Admitted to University Hospital of Martinique with subarachnoid hemorrhage of aneurysmal origin between 01\u002F01\u002F2013 and 31\u002F12\u002F2021,\n* Informed patient\u002Fnext-of-kin\u002Ftreating physician consent for research participation.\n\nExclusion Criteria:\n\n* Other causes of subarachnoid hemorrhage of non-aneurysmal origin (traumatic, arteriovenous malformation, cerebral tumor, cerebral thrombophlebitis).",{"count":142,"type":21},122,"The aim of our study is to analyze mortality and sequelae of subarachnoid hemorrhage of aneurysmal origin in hospitalized patients in Martinique. Predictive factors of poor prognosis will also be analyzed.",[145],"Subarachnoid Hemorrhage of Aneurysmal Cause",[118,147,148,149,150,151],"Ruptured intracranial aneurysm","Modified Rankin score","Mortality","Patient autonomy","Patient dependence",{"date":128,"type":36},{"date":154,"type":36},"2024-07-19",{"date":156,"type":21},"2025-04-01",{"name":42,"class":43},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":44},"100544167","systemic-lupus-erythematosus-and-chlordecone-impregnation-in-martinique-100544167","NCT06365359","Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique","LUNEK","Inclusion Criteria:\n\n* Patients with systemic lupus erythematosus according to the ACR 1997 or ACR\u002FEULAR 2019 criteria,\n* Present in the active line of the internal medicine department of the Martinique University Hospital since 2005,\n* Whose illness has been progressing for at least 3 years,\n* Living in Martinique or Guadeloupe for at least 1 year,\n* Patients who have given their free, informed and written consent.\n\nExclusion Criteria:\n\n* Patients for whom kidney disease cannot be authenticated or ruled out (refusal, contraindication or impossibility of renal biopsy),\n* Patients without social security coverage,\n* Current legal protection,\n* Patients who have not given their consent to the use of their data,\n* Pregnant or breastfeeding women.",{"count":166,"type":21},200,"Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of the food chain and the majority of the population of the French West Indies by chlordecone.\n\nEpidemiological studies conducted in the French West Indies have shown that exposure to chlordecone at the levels observed is associated with an increased risk of developing several diseases, including premature birth and prostate cancer. Many of the adverse effects associated with chlordecone could be explained by its estrogenic hormonal properties, and systemic lupus erythematosus (SLE) is an autoimmune disease whose sensitivity to estrogen is well known and is reflected by 1) its clear predominance in women, 2) its predominance in women of childbearing age, 3) its risk of exacerbation in the event of pregnancy.\n\nChlordecone has the potential to modify the activity of SLE through mechanisms other than its pro-estrogenic effects. In rats, chlordecone was observed to induce alterations such as a reduction in lymphocyte count, thymic atrophy, and a decrease in splenic germinal centers and NK cells.\n\nIn a mouse model of systemic lupus erythematosus (SLE), exposure to chlordecone results in increased production of immune complexes and anti-DNA antibodies, which are markers of disease activity and monitoring.\n\nChlordecone also has a cellular effect that reduces the apoptosis of potentially auto-reactive lymphocytes and stimulates the production of GM-CSF, IL-2, TNF-alpha, and IFN-gamma. The latter is central to the pathophysiology of SLE. While experimental studies suggest a potential impact of chlordecone on SLE, no human studies have been conducted to date, and the chlordecone impregnation of lupus patients in Martinique remains unknown.\n\nThe most serious and feared complication of SLE is kidney damage. Kidney damage from the disease and the necessary immunosuppressive treatments can lead to significant morbidity and mortality, including death and end-stage chronic renal failure. Therefore, it is important to manage the disease carefully. Suspected lupus nephritis is confirmed by a renal biopsy, which allows for formal diagnosis and categorization into several classes. Suspected cases are identified by a proteinuria to creatininuria ratio greater than 0.5 g\u002Fg (or 24-hour proteinuria greater than 0.5g).\n\nThe objective of this project is to determine whether there is a positive association between lupus nephritis occurrence in patients followed by the internal medicine department of the Martinique University Hospital and organochlorine pesticide chlordecone impregnation.",[169,170],"Systemic Lupus Erythematosus","Renal Disease",[169,172,173,170],"Chlordecone impregnation","Organochlorine pesticide (chlordecone, p,p'-DDE, βHCH, γHCH, PCB 153)",{"date":128,"type":36},{"date":176,"type":36},"2025-01-02",{"date":178,"type":21},"2026-09-02",{"name":42,"class":43},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":113,"phases":190,"briefSummary":191,"conditions":192,"keywords":197,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":44},"100527886","effectiveness-of-musicotherapy-in-reducing-pain-induced-by-leg-ulcer-care-100527886","NCT06153589","Effectiveness of Musicotherapy in Reducing Pain Induced by Leg Ulcer Care","Effectiveness of Musicotherapy in Reducing Pain Induced by Leg Ulcer Care: a Randomized, Controlled, Open-label, Parallel-arm Study","MUS-ICAT","Inclusion Criteria:\n\n* Adult patient,\n* Patient followed at the M@diCICAT healing center requiring wound debridement :\n\n  * For a venous or arterial ulcer or necrotizing angiodermatitis of the lower limbs,\n  * Having the ability to verbalize about their pain (communicating),\n  * With a planned debridement time of less than 40 minutes.\n* Patient affiliated to or beneficiary of a social security scheme,\n* Patient having given free, informed and express consent.\n\nExclusion Criteria:\n\n* Patient with a diabetic foot (loss of sensitivity-neuropathy),\n* Patient not requiring a debridement session,\n* Patient with an infected ulcer (abscess, etc.),\n* Patient with critical ischemia,\n* Patient with hearing problems,\n* Patient with cognitive disorders,\n* Patient placed under legal protection, guardianship or curatorship,\n* Pregnant or breastfeeding woman.",{"count":189,"type":21},180,[115],"Venous leg ulcer is the final stage of chronic venous disease and only develops due to advanced chronic venous insufficiency. The problems caused by venous disease are initially minor and often neglected, but can impact the quality of life of patients.\n\nThe prevalence of leg ulcers is estimated at 1% of the general population and 3% to 5% of subjects over 65 years old. Its prevalence increases with age in both men and women.\n\nManaging chronic ulcers requires a certain number of care procedures, including debridement.\n\nThe act of treatment by mechanical debridement is little relieved by the analgesics given beforehand, and can be painful, with risks of bleeding.\n\nMusicotherapy, particularly the U-shaped method, has shown its effectiveness in the treatment of pain and anxiety in several areas (geriatrics, intensive care, rheumatology, oncology, etc.).\n\nThe standardized musicotherapy method of the U-shaped sequence was developed and initially evaluated by clinical studies coordinated by the INSERM unit U1061 (Pr. Jacques Touchon; Dr. Stéphane Guétin).\n\nFollowing the publication of numerous controlled, randomized studies presenting results on the effectiveness in the treatment of pain and anxiety, a digital application was developed in order to standardize the method. The Music Care health application is now a Class 1 Medical Device, with CE marking obtained.\n\nThis \"U-shaped sequence\" is standardized and has been clinically validated, which makes Music Care a unique tool available for pain relief.\n\nNo studies have been found in the literature regarding the use of music therapy during debridement care.",[193,194,195,196],"Debridement Care","Leg Ulcer","Leg Ulcers Venous","Pain",[198,199,196],"Debridement","Venous leg ulcer",{"date":128,"type":36},{"date":202,"type":36},"2025-01-08",{"date":204,"type":21},"2026-09-08",{"name":42,"class":43},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":52,"sex":213,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":44},"100514717","weight-changes-among-martinican-prisoners-100514717","NCT05982132","Weight Changes Among Martinican Prisoners","NUTRI-LAJÔL","Inclusion Criteria:\n\n* all men newly incarcerated in martinican jail during inclusion period\n* age between 18 and 44 years old\n* having given his consent\n\nExclusion Criteria:\n\n* female\n* 44 years old and up\n* not understanding or speaking French or English","MALE","44 Years",{"count":216,"type":21},227,"Assessment of body weight change among prisoners in Martinique between admission in jail and 3 months later expressed as a percentage of admission weight. Intensity of physical activities, nutrition intakes and psychological state are also studied to describe associated factors to body weight change.",[219,220],"Weight Gain","Weight Loss",[222,223,224,95,225],"Prisoners","Body weight","Male","Epidemiology","2025-02-20",{"date":228,"type":36},"2025-02-24",{"date":230,"type":36},"2023-01-11",{"date":232,"type":21},"2025-08",{"name":42,"class":43},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":242,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":246,"conditions":247,"keywords":252,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":44},"100426957","dengue-vaccine-strategy-in-children-aged-9-to-17-years-in-the-french-caribbean-100426957","NCT04839757","Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean","Preparing for the Use of a Dengue Vaccine in the French Caribbean Islands of Martinique and Guadeloupe : the DengueSEA Study","DengueSEA","CHILDREN\n\nInclusion Criteria for children:\n\n* Any child aged 9 to 17 years presenting to one of the hospital departments participating in the study at the University Hospitals of Martinique or Guadeloupe\n* Need to take a blood sample or place a peripheral venous line for the management of the child\n* Residence in Martinique or Guadeloupe since at least one year\n* Information on the study given to the child and his\u002Fher parent or legal guardian\n* Collection of the parent's or legal guardian's non-objection to the child's participation\n\nExclusion Criteria for children:\n\n* Presence of fever or suspected acute infection\n* Presence of an immune deficiency or any other dysimmune condition\n\nPARENTS\n\nParental inclusion criteria (\"vaccine acceptability\" survey)\n\n* Collection of the parent's or legal guardian's non-objection to participate in the Dengvaxia® vaccine acceptability survey\n* Comprehension of spoken and written French\n\nNon-inclusion criteria for parents (vaccine acceptability survey)\n\n\\- None of the above","9 Years","17 Years",{"count":245,"type":21},590,"Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits. The 2018 European marketing authorization of the tetravalent chimeric yellow fever \u002F dengue vaccine (Dengvaxia®) is a major step forward in the fight against the disease. Dengvaxia® is indicated for the prevention of dengue due to serotypes DENV 1-4 in subjects aged 9 to 45 years with a history of infection with the dengue virus and living in endemic areas (seroprevalence of at least 70% in the target population).\n\nDengue seroprevalence data in the French Caribbean territories of Martinique and Guadeloupe dates back to 2011 and concerns only adult blood donors aged 18 to 70 years. To date, no data exists for individuals aged 9 to 17 years in the region.\n\nIn order to implement an optimal vaccine introduction strategy for these territories, the main aim of the DengueSEA study is to estimate the seroprevalence of the Dengue viruses (DENV 1-4) in 9-17 year olds giving a blood sample as part of care in hospital departments of the French Caribbean islands of Martinique and Guadeloupe.",[248,249,250,251],"Dengue","Vaccination","Seroprevalence","Infectious Disease",[253,254,255,256,257,258],"dengue","seroprevalence","children","adolescents","vaccination strategy","French Carribean",{"date":260,"type":36},"2025-02-21",{"date":262,"type":36},"2021-06-03",{"date":264,"type":21},"2026-02",{"name":42,"class":43},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":275,"conditions":276,"keywords":281,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":44},"100539505","effects-of-bothrops-spp-snake-envenomation-on-willebrand-factor-activity-in-martinique-and-french-guiana-100539505","NCT06304714","Effects of Bothrops Spp. Snake Envenomation on Willebrand Factor Activity in Martinique and French Guiana","Abnormalities of Plasma Willebrand Factor Activity Induced by Bothrops Snakebites Endemic to Martinique and French Guyana","WBOTHROPS","Inclusion Criteria:\n\n* Men or Women, at least 18 years old\n* Be admitted to the Emergency Department of the Martinique University Hospital or the Cayenne University Hospital\n* Be the victim of a confirmed Bothrops snake bite in Martinique or French Guyana. The formal identification of the snake by the patient or his entourage is imperative.\n* Have a confirmed diagnosis of stage III envenomation (regional oedema of the limb and\u002For moderate general symptoms such as moderate hypotension, malaise, vomiting, abdominal pain, diarrhoea) and stage IV (extensive oedema reaching the trunk and\u002For severe general symptoms such as prolonged hypotension, shock, anaphylactoid reaction, visceral damage)\n* Be able to receive and understand information related to the research\n* Be able to freely give verbal consent to participate in the proposed research\n* Be able to freely give written informed consent to participate in the plasmathèque\n* Be affiliated to the general social security system\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* People who have been treated for snakebite with Bothrops anti-venom Bothrofav® or Antivipmyn-tri®.\n* Known disorders of haemostasis such as haemophilia A (factor VIII deficiency), haemophilia B (factor IX deficiency), vitamin K deficiency, hepato-cellular insufficiency, presence of circulating anticoagulant factors\n* Disseminated intravascular coagulation (DIC)\n* Constitutional and acquired Von Willebrand disease\n* Constitutional and acquired thrombopathies\n* Idiopathic thrombocytopenic purpura\n* Person under legal protection (guardianship, curatorship, safeguard of justice), and person deprived of liberty.",{"count":54,"type":21},"In 2017, the World Health Organization placed snakebites at the top of its list of neglected tropical diseases in an effort to facilitate funding for prevention programs, improve access to anti-venom, and stimulate new research in this area. Between 5 and 25 cases per 100 000 inhabitants are reported per year in French Guiana and Martinique. Before the era of anti-venom immunotherapy, envenomations by Bothrops snake bites in French Guiana and Martinique could quickly become life-threatening with a mortality rate close to 30%. Today, the administration of fragments of Fab or (Fab')2 immunoglobulins gives anti-venoms an excellent capacity to neutralise venom toxins, which has reduced mortality to less than 1% in the case of early hospital treatment In French Guiana, envenomation by Bothrops bites is characterized by local signs such as intense pain, rapidly expanding oedema, haemorrhagic phlyctenes and sometimes muscle necrosis. The local inflammatory and haemorrhagic damage is related to the enzymatic activities of the toxins contained in the venom (metallo-proteinases, disintegrins, and phospholipases A2, in particular). At the systemic level, venom serine proteases and metalloproteinases activate the coagulation cascade by multiple mechanisms (activation of coagulation factors X and V and of protrombin, thrombin-like and fibrinogenolytic enzymatic properties) and are responsible for the collapse of coagulation factors making the blood incoagulable. The metalloproteinases \"hemorrhagins\" destroy the vessel wall and are the cause of locoregional and systemic hemorrhage.\n\nEnvenomations by bites of Bothrops lanceolatus in Martinique have particular characteristics. Despite the genetic similarity with their congeners in French Guiana, envenomation by bites of Bothrops lanceolatus is characterized by the development of very intense local inflammatory signs (little haemorrhage) and the occurrence of thrombotic complications such as cerebral, pulmonary or myocardial infarction. The mechanisms behind this thrombotic presentation are not known. The large amount of metalloproteinases in the composition of Bothrops lanceolatus venom is believed to be responsible for destruction of vascular endothelium and pro-thrombotic state. Bothrops lanceolatus bite envenomations have been reported to be frequently complicated by generalized infections, disseminated intravascular coagulation and the occurrence of multi-visceral failure syndrome. This observation suggests abnormalities in endothelial function in which changes in Willebrand factor expression have been implicated.\n\nThe investigators hypothesize that plasma Willebrand factor (VW) activity and the intensity of endothelial activation are different depending on the Bothrops snake species involved in the bites in Guyana and Martinique. Due to the specific properties of the venoms of each Bothrops species, the activity of the Willebrand factor (VW) and the consequences in terms of endothelial activation would be different and responsible for the clinico-biological characteristics according to the geographical origin of the snakes.\n\nThe investigators will demonstrate that the accumulation of Willebrand factor (VW) and the increase in its activity are responsible for the endothelial activation and micro-thrombosis observed during envenomations by Bothrops lanceolatus bites, whereas the decrease in its activity induced by the venoms of endemic Bothrops from Guyana is responsible for haemorrhagic phenomena.\n\nThis study will highlight the importance of changes in Willebrand factor activity on endothelial activation and the initiation of micro-thrombosis in the case of Bothrops lanceolatus envenomations and on primary haemostasis and bleeding disorders in the case of endemic Bothrops in Guyana. This new knowledge is important insofar as individualised therapeutic management can be proposed. Indeed, several studies have shown that adjuvant treatment of thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, with blood products (fresh frozen plasma) or plasma exchange, improves endothelial dysfunction and the prognosis of patients.",[277,278,279,280],"Snake Envenomation","Thrombi","Coagulopathy","Hemorrhage",[282,283,284,285,286,287],"Snakebite envenomation","French Caribbean (Martinique, French Guiana)","Bothrops species","Von Willebrand Factor","endothelial activity","haemostasis","2024-09-24",{"date":290,"type":36},"2024-09-26",{"date":292,"type":36},"2024-08-02",{"date":294,"type":21},"2025-10-08",{"name":42,"class":43},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":44},"100498718","contribution-of-psychological-autopsy-to-the-understanding-of-suicidal-behaviors-in-french-overseas-territories-100498718","NCT05773898","Contribution of Psychological Autopsy to the Understanding of Suicidal Behaviors in French Overseas Territories","AUTOPSOM","Inclusion Criteria:\n\n* Persons close of the deceased\n* Persons who knew about his\u002Fher childhood\n* Age 18 or over\n* Interviewed for the study between 2 and 11 months after the suicide\n\nExclusion Criteria:\n\n* People with neuropsychiatric disorders that may affect the quality of the information collected, cognitive (memory and expression) and judgmental functions\n* People who refuses to participate\n* Persons referred to articles L.1121-6, L.1121-7, L. 1121-8 L.1121-1-2 of the French Public Health Code.",{"count":84,"type":21},"The mains objectives of our project are to coordinate the monitoring of suicides and to identify common or specific suicide risk factors in four overseas DROM-COM (French Polynesia, La Reunion, French Guiana and Martinique) by comparing to a site in mainland France (Amiens). A mixed approach (quantitative and qualitative) will be used, based on semi-directed interviews of the psychological autopsy type.",[306,307,308],"Suicide","Mental Disorders","Prognostic Factors",[306,310,311,312,313,314],"Psychological autopsies","epidemiology","risk factors","psycholinguistic approach","French overseas territories",{"date":290,"type":36},{"date":317,"type":36},"2024-01-25",{"date":319,"type":21},"2025-04",{"name":42,"class":43},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":330,"conditions":331,"keywords":333,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":347},"100560677","evaluation-of-the-vittel-criteria-for-pre-hospital-triage-of-severe-trauma-patients-in-the-french-west-indies-and-in-french-guiana-100560677","NCT06580262","Evaluation of the Vittel Criteria for Pre-hospital Triage of Severe Trauma Patients in the French West Indies and in French Guiana","TRAUMA-DOM","Inclusion Criteria:\n\n* Minor patients (2-17 years) and adults (≥ 18 years).\n* Patients treated in the emergency units of the hospitals participating in the study, whether they were brought by a SAMU\u002FSMUR team, by a rescue and victim assistance vehicle or arrived directly.\n* Patients suspected of severe trauma, defined as trauma likely to have caused multiple injuries and\u002For threatening the vital or functional prognosis.\n* Patient if he is able to, or representative of the patient in case of incapacity, having given his agreement for the use of his medical data for this research.\n\nExclusion Criteria:\n\n* Absence of consent from the patient, or representative to the use of the data for the research.",{"count":329,"type":21},700,"Severe trauma is a public health problem because it is the leading cause of death in young people and the third leading cause of death in France for all ages. These injuries will cause anatomical and functional after-effects that are sometimes permanent, and are therefore among the leading causes of acquired disability in France.\n\nThe Vittel criteria constitute a decision-making algorithm of 24 criteria for triage of trauma patients. The presence of only one criterion out of the 24 must direct the patient to a trauma referral center. The existence of only one trauma referral center per territory questions the relevance of using the Vittel criteria in the French Antilles and Guiana.\n\nIt therefore seems important that the relevance of the different Vittel criteria be reassessed in our territories, where the typology of patients and the urban network is different compared to that of mainland France. are a common cause of severe trauma, followed by assaults or fights, accidents at work, during leisure or at home, falls from a great height, and weapon-related injuries. Special and rapid care is then necessary.\n\nThis is why trauma severity criteria and triage scores are used to target these serious patients and direct them to the appropriate healthcare facilities.\n\nThe Vittel criteria constitute a decision-making algorithm of 24 criteria for triage of trauma patients. The presence of only one criterion out of the 24 must direct the patient to a trauma referral center. The existence of only one trauma referral center per territory questions the relevance of using the Vittel criteria in the French Antilles and Guiana.\n\nIt therefore seems important that the relevance of the different Vittel criteria be reassessed in Martinique, Guadeloupe and french Guiana, french overseas territories, where the typology of patients and the urban network is different compared to that of mainland France.",[332],"Severe Trauma",[334,335,336,337,338],"Trauma","Severe trauma","Vittel criteria","Hospital emergency","Triage score","2024-08-28",{"date":341,"type":36},"2024-08-30",{"date":343,"type":21},"2024-10",{"date":345,"type":21},"2025-12",{"name":42,"class":43},2,{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":113,"phases":358,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":380},"100378753","phase-4-comparing-two-antibiotic-therapy-periods-3-versus-7-days-in-patients-with-mild-leptospirosis-and-seen-at-the-hospital-in-5-french-overseas-departments-martinique-guadeloupe-french-guiana-reunion-mayotte-100378753","NCT04211649","Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)","Multicenter, Randomized, Open-label Non-inferiority Trial, Comparing Two Antibiotic Therapy Periods (3 Versus 7 Days) in Patients With Mild Leptospirosis and Seen at the Hospital in 5 French Overseas Departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)","LEPTO3","Inclusion Criteria:\n\n1. Patient aged 18 years and above at the time of study inclusion\n2. Patient consulting at a recruiting hospital center\n3. Clinical and biological suspicion of leptospirosis, confirmed by serological rapid testing or PCR at most 72 hours after start of antibiotic treatment\n4. Affiliated or beneficiary of a social security scheme (For French Guiana, patients benefiting from State Medical Aid (AME) will be considered, in accordance with the provisions of article L1121-8-1 of the Public Health Code\n5. Acceptance of participation in the clinical trial and in the follow-up process at 7 and 21 days (from start of antibiotic therapy)\n6. Provision of a signed consent form from the study participant\n\nExclusion Criteria:\n\n1. Presence of one of the severity criteria appearing between the time of first patient care at the hospital and study inclusion:\n\n   1. Hemodynamic failure with onset of septic shock defined by persisting hypotension requiring vasopressor amines to maintain mean arterial pressure ≥65 mm Hg and blood lactates \\>2 mmol\u002FL despite adequate volume resuscitation (73)\n   2. Hematologic failure with hemoglobin \\\u003C7 g \u002F dL requiring red blood cell transfusion (74) or platelets \\\u003C20 G \u002F L requiring platelet transfusion (75)\n   3. Ventilatory failure defined by PaO2 \u002F Fi O2 ratio \\\u003C300 mmHg (76) or resort to mechanical ventilation\n   4. Renal failure defined by serum creatinine \\> 301 μmol \u002F L 76) or resort to renal dialysis\n   5. Hepatic failure defined by total bilirubinemia\\> 101 μmol \u002F L (76)\n   6. Heart failure (eg: ECG anomalies, myocarditis, cardiogenic shock)\n   7. Neurologic affection such as meningitis, encephalitis, intracerebral hemorragia, stroke\n   8. Ocular symptoms such as uveitis.\n   9. Hemoptysis, lesional pulmonary oedema for pulmonary affection\n   10. Hemorrhagic syndrome\n2. Diagnosis of another bacterial infection documented during initial patient assessment (e.g. Gram-negative bacteremia, digestive tract infection, bacterial pneumonia)\n3. Intake of antibiotics, active on leptospirosis, the week before clinical and biological suspicion of leptospirosis\n4. Leptospirosis diagnosis by PCR or serological rapid testing after the 7th day from symptom onset\n5. Pregnant or lactating woman, or woman of childbearing age without effective contraception\n6. Previous hypersensitivity to β-lactams and doxycycline or contraindication to the latter's use\n7. Ongoing treatment that is contraindicated with one of the study treatments",{"count":357,"type":21},220,[359],"PHASE4","Leptospirosis is a globally distributed neglected tropical disease affecting subtropical and tropical areas, such as the Caribbean and the Indian Ocean, with favorable climatic conditions for disease transmission. It shows a strong seasonality, with epidemic potential especially after heavy rainfall. A recent systematic review by Costa et al. (2015) places leptospirosis among the leading zoonotic causes of morbidity and mortality worldwide, with 1.03 million cases and 58,900 deaths each year.\n\nLeptospirosis is an important public health problem, particularly within economically vulnerable populations. It is also emerging as a health threat in new settings due to globalization and climate change. Disasters and extreme weather events are recognized to precipitate epidemics.\n\nClinical manifestations are highly polymorphic, ranging from an anicteric, influenza-like form to severe forms with hepato-renal or pulmonary failures which are associated with high mortality.\n\nAntibiotic therapy should be prescribed early, as soon as leptospirosis is suspected and preferably within the first 5 days, before leptospira spread to the tissues. In the treatment of mild forms, usual antibiotics are oral amoxicillin or doxycycline for a standard treatment duration of 7 days. In hospitalized cases of leptospirosis, parenteral antibiotic therapy with ceftriaxone is often favored as first-line therapy.\n\nThe most widely used antibiotics in the French Caribbean and Indian Ocean regions are amoxicillin, doxycyclin and third generation cephalosporins such as ceftriaxone.\n\nResearch hypothesis:\n\nThe effects of shorter antibiotic therapy periods for other infectious diseases have been explored by several authors. The efficacy of short ceftriaxone treatment has been highlighted for typhoid fever or meningococcal meningitis. In a retrospective series of 21 cases, the interest of short treatment periods (3-6 days) for mild and severe leptospirosis has also been described. A minimal 3-day therapy period would seem necessary in order to biologically confirm leptospirosis diagnosis and to rule out other community-acquired infections.\n\nOur study proposal is the conduct of a non-inferiority trial comparing a shortened antibiotic therapy period of 3 days with the standard treatment period of 7 days in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte).\n\nOriginality and innovative aspects:\n\nTo our knowledge, the efficacy of a 3-day antibiotic therapy for mild leptospirosis, as compared to the standard 7 day period, has not yet been explored.\n\nIn addition, the LEPTO3 study will be among the first clinical trials to focus on the endemic public health problem, which is leptospirosis, at a large geographical level (Caribbean and Indian Ocean regions) and to involve a high level of collaboration between medical and scientific teams of these territories.",[362],"Mild Leptospirosis",[364,365,366,367,368,369,370,371],"neglected infectious","tropical diseases","emerging diseases","mild leptospirosis","insular context","antibiotics","short treatment period","non-inferiority trial","2024-07-16",{"date":374,"type":36},"2024-07-18",{"date":376,"type":21},"2024-10-01",{"date":378,"type":21},"2028-02-01",{"name":42,"class":43},5,{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":113,"phases":391,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":44},"100518106","effects-of-probiotic-oral-intake-on-plasma-chlordecone-kepone-concentrations-in-individuals-environmentally-exposed-to-pesticide-in-martinique-100518106","NCT06026228","Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique.","Effects of Oral Intake of the Probiotic Limosilactobacillus Reuteri on Plasma Chlordecone (Kepone) Concentrations (Chlordeconemia) in Individuals Environmentally Exposed to the Organochlorine Pesticide in Martinique : an Exploratory Pilot Study","CHLOR-DETOX","Inclusion Criteria:\n\n* Male or female, 18 years of age or older\n* Seen in clinical toxicology consultation at the CHU of Martinique during the study period\n* With an initial chlordeconemia \\> 1μg\u002FL on a test less than 1 month old at the time of study inclusion\n* Affiliated to a social security scheme\n* Having received informed information on research\n* Having freely given written and informed consent to participate in the research\n\nExclusion Criteria:\n\n* History of cancer\n* Recent infections less than 6 months old\n* Known digestive diseases: chronic diarrhoea, ulcerative colitis, Crohn's disease, pancreatitis\n* Digestive procedures less than 6 months old.\n* Intrahepatic cholestasis less than 6 months old\n* Extrahepatic cholestasis less than 6 months old\n* Use of cholestyramine or ursodeoxycholic acid in the previous 3 months\n* Consumption of food (non-ordinary yoghurt, etc.) or supplements (tablets, drops, capsules, etc.) containing L. reuteri or any other probiotic within the previous 2 weeks.\n* Antibiotics taken in the previous 4 weeks.\n* Immune deficiency secondary to a pathology (lymphoma, leukaemia) or medical treatment (immunosuppressant, corticoid, chemotherapy).\n* Women who are unable to obtain contraception during the trial\n* Persons referred to in articles L.1121-5, L.1121-7, L. 1121-8 of the Public Health Code:\n\n  * Pregnant woman, parturient or breastfeeding mother\n  * Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n  * Persons deprived of their liberty by a judicial or administrative decision,\n  * Persons staying in a health or social care institution for purposes other than research\n* Persons subject to psychiatric care under Articles L. 3212-1 and L. 3213-1 of the Public Health Code.",{"count":390,"type":21},100,[115],"The CHLOR-DETOX study is a single-centre, double-blind, prospective, interventional, controlled, exploratory pilot study on subjects environmentally exposed to the organochlorine pesticide (kepone or chlordecone, CLD) in the French Caribbean (Martinique island). To our best knowledge, it is the first clinical trial in such subjects evaluating the potential effect of oral probiotic intake (Limosilactobacillus reuteri) on the reduction of CLD plasma levels (chlordeconemia) and fecal excretion, thus concurring to the reduction of CLD toxicity in study subjects.",[394],"Chlordecone (Kepone) Toxicity",[396,397,398,399,400],"Chlordecone toxicity","Probiotics","Gut elimination","entero-hepatic cycle","plasma level concentration","2024-02-19",{"date":403,"type":36},"2024-02-21",{"date":405,"type":21},"2024-04",{"date":407,"type":21},"2026-10",{"name":42,"class":43},{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":113,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":44},"100400293","assessment-of-a-special-modality-of-back-muscles-strengthening-for-postural-deformations-in-parkinsonian-patient-100400293","NCT04492345","Assessment of a Special Modality of Back Muscles Strengthening for Postural Deformations in Parkinsonian Patient","Impact of Isocinetism on the Disorders of the Spinal Statics of the Parkinsonian Patient","ISOPARK","Inclusion Criteria:\n\n* Patient with Parkinson's disease or atypical parkinsonian syndrome\n* Age ≥18 years\n* Patient with postural disorders with a cervical arrow\\> 6cm in the sagittal plane and \u002F or the axis C7S2 different from 0 in the frontal plane\n* UPDRS between 10 and 25\u002F108.\n* Antiparkinsonian treatment stabilized for 8 weeks\n* MMS test\\> 25\n* Insured person or beneficiary of social security\n\nExclusion Criteria:\n\n* Patient with a neurological condition other than parkinsonian syndrome\n* Patient with rheumatic disease\n* Patient with a history of trunk surgery\n* Patient with a brain stimulator\n* Cardiac pathology not stabilized\n* Incapacitated adult, or under guardianship, or under curatorship or under judicial protection curatorship","85 Years",{"count":54,"type":21},[115],"Parkinson's patients have postural disorders. These disorders are frequent in Martinique. Physiotherapeutic rehabilitation is essential because these disorders are generally non dopa-sensitive.",[422,423,424],"Parkinson Disease","Physical Medicine","Rehabilitation","2024-02-12",{"date":427,"type":36},"2024-02-14",{"date":429,"type":36},"2021-06-11",{"date":431,"type":21},"2026-06",{"name":42,"class":43},""]